Switch theme
Sign up to access all valuation multiples
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
2006
121
LTM Revenue $0.7M
LTM EBITDA -$124M
-$8.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Adverum Biotechnologies has a last 12-month revenue of $0.7M and a last 12-month EBITDA of -$124M.
In the most recent fiscal year, Adverum Biotechnologies achieved revenue of $3.6M and an EBITDA of -$118M.
Adverum Biotechnologies expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Adverum Biotechnologies valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $3.6M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$151M | -$118M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -3287% | XXX | XXX | XXX |
| Net Profit | -$146M | -$155M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -4293% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Adverum Biotechnologies's stock price is $3.
Adverum Biotechnologies has current market cap of $71.4M, and EV of -$8.6M.
See Adverum Biotechnologies trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$8.6M | $71.4M | XXX | XXX | XXX | XXX | $-5.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Adverum Biotechnologies has market cap of $71.4M and EV of -$8.6M.
Adverum Biotechnologies's trades at -12.1x LTM EV/Revenue multiple, and 0.1x LTM EBITDA.
Analysts estimate Adverum Biotechnologies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Adverum Biotechnologies and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$8.6M | XXX | XXX | XXX |
| EV/Revenue | -2.4x | XXX | XXX | XXX |
| EV/EBITDA | 0.1x | XXX | XXX | XXX |
| P/E | -0.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAdverum Biotechnologies's NTM/LTM revenue growth is -100%
Adverum Biotechnologies's revenue per employee for the last fiscal year averaged $30K, while opex per employee averaged $1.1M for the same period.
Over next 12 months, Adverum Biotechnologies's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Adverum Biotechnologies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Adverum Biotechnologies and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -3287% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -21% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $30K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1387% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2158% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 3544% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Adverum Biotechnologies acquired XXX companies to date.
Last acquisition by Adverum Biotechnologies was XXXXXXXX, XXXXX XXXXX XXXXXX . Adverum Biotechnologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Adverum Biotechnologies founded? | Adverum Biotechnologies was founded in 2006. |
| Where is Adverum Biotechnologies headquartered? | Adverum Biotechnologies is headquartered in United States of America. |
| How many employees does Adverum Biotechnologies have? | As of today, Adverum Biotechnologies has 121 employees. |
| Who is the CEO of Adverum Biotechnologies? | Adverum Biotechnologies's CEO is Dr. Laurent Fischer, M.D.. |
| Is Adverum Biotechnologies publicy listed? | Yes, Adverum Biotechnologies is a public company listed on NAS. |
| What is the stock symbol of Adverum Biotechnologies? | Adverum Biotechnologies trades under ADVM ticker. |
| When did Adverum Biotechnologies go public? | Adverum Biotechnologies went public in 2014. |
| Who are competitors of Adverum Biotechnologies? | Similar companies to Adverum Biotechnologies include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Adverum Biotechnologies? | Adverum Biotechnologies's current market cap is $71.4M |
| What is the current revenue of Adverum Biotechnologies? | Adverum Biotechnologies's last 12-month revenue is $0.7M. |
| What is the current EBITDA of Adverum Biotechnologies? | Adverum Biotechnologies's last 12-month EBITDA is -$124M. |
| What is the current EV/Revenue multiple of Adverum Biotechnologies? | Current revenue multiple of Adverum Biotechnologies is -12.1x. |
| What is the current EV/EBITDA multiple of Adverum Biotechnologies? | Current EBITDA multiple of Adverum Biotechnologies is 0.1x. |
| Is Adverum Biotechnologies profitable? | Yes, Adverum Biotechnologies is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
